UBS analyst Eliana Merle initiated coverage of Altimmune (ALT) with a Buy rating and $26 price target The firm sees Altimmune as “highly differentiated” in the metabolic space, with near-term upside from likely positive metabolic dysfunction-associated steatohepatitis data in Q2 of 2025. The firm has “high conviction” in pemvidutide’s success in the Phase 2b trial and assigns a 50% probability of success. It believes Altimmune’s long-term opportunities are underappreciated.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALT:
- Altimmune says pemvidutide given ‘clean safety bill of health’ by FDA
- Altimmune says ‘something raised attention of FDA’
- Altimmune announces inducement grants under Nasdaq listing rule
- Altimmune appoints Greg Weaver as CFO
- Options Volatility and Implied Earnings Moves This Week, November 11 – November 15, 2024
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
